These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 27421652)

  • 1. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
    BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
    Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
    Chen L; Yang G; Dong H
    Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus induces G
    Chen G; Ding XF; Bouamar H; Pressley K; Sun LZ
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C244-C252. PubMed ID: 31116586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.
    Wang Y; Liu J; Qiu Y; Jin M; Chen X; Fan G; Wang R; Kong D
    Oncotarget; 2016 Apr; 7(15):19897-909. PubMed ID: 26918351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM.
    Cheng X; Tan S; Duan F; Yuan Q; Li Q; Deng G
    Breast Cancer; 2019 Nov; 26(6):766-775. PubMed ID: 31172425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
    Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
    Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Wong C; Wang X; Smith D; Reddy K; Chen S
    Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.